GlassScriptPhysician profile
Georgia C Mclendon
NPI 1841752268
$3,516.69
in general payments reported to CMS, 2019-2025
27 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $380 · 2023: $1,665 · 2024: $1,063 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,136.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $711.55 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $530.89 | 2022-2025 | |
| Lilly USA, LLC | $333.59 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $290.31 | 2022-2025 | Repatha, Evenity, Otezla |
| Exact Sciences Corporation | $216.68 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $175.46 | 2022-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Radius Health, INC. | $164.62 | 2022-2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $161.46 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $142.44 | 2022-2025 | Airsupra, Farxiga |
| Pfizer INC. | $140.52 | 2023 | |
| Ibsa Pharma INC. | $109.29 | 2022-2025 | Tirosint, Tirosint, Licart |
| Ucb, INC. | $84.97 | 2022-2024 | Nayzilam, Briviact |
| Irhythm Technologies, INC. | $49.52 | 2023 | Zio Xt Patch |
| Sanofi-Aventis U.S. LLC | $49.26 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.43 | 2023 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $39.59 | 2022-2023 | Strensiq |
| Boston Scientific Corporation | $39.18 | 2023 | Vercise |
| Bayer Healthcare Pharmaceuticals INC. | $36.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.44 | 2022-2023 | Trulance, Xifaxan |
| Dexcom, INC. | $27.10 | 2024 | Dexcom G6 Transmitter |
| Argenx US, INC. | $26.30 | 2023 | Vyvgart |
| Viiv Healthcare Company | $25.47 | 2024 | Apretude |
| Alvogen INC | $24.73 | 2023 | Teriparatide |
| Inspire Medical Systems, INC. | $22.54 | 2024 | Inspire |
| Gilead Sciences, INC. | $16.98 | 2023 | |
| Idorsia Pharmaceuticals US INC | $14.23 | 2022 | |
| Eisai INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgia Mclendon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.